Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Tax Provisions (2016 - 2025)

Enanta Pharmaceuticals' Tax Provisions history spans 12 years, with the latest figure at $24000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions rose 105.77% year-over-year to $24000.0; the TTM value through Dec 2025 reached -$1.2 million, down 405.76%, while the annual FY2025 figure was -$1.7 million, 960.1% down from the prior year.
  • Tax Provisions reached $24000.0 in Q4 2025 per ENTA's latest filing, down from $32000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $48.5 million in Q3 2021 to a low of -$9.4 million in Q2 2021.
  • Average Tax Provisions over 5 years is $2.5 million, with a median of -$34000.0 recorded in 2022.
  • The largest YoY upside for Tax Provisions was 1044.3% in 2023 against a maximum downside of 70400.0% in 2023.
  • A 5-year view of Tax Provisions shows it stood at -$36000.0 in 2021, then increased by 5.56% to -$34000.0 in 2022, then plummeted by 1729.41% to -$622000.0 in 2023, then soared by 33.12% to -$416000.0 in 2024, then soared by 105.77% to $24000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Tax Provisions are $24000.0 (Q4 2025), $32000.0 (Q3 2025), and $29000.0 (Q2 2025).